Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2015, Pages 1137-1144

  de Ligt, Marlies ^a   Timmers, Silvie ^a   Schrauwen, Patrick ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Mitochondria; Obesity; Resveratrol; Sirtuin; Type 2 diabetes

Indexed keywords

RESVERATROL; AMP-ACTIVATED PROTEIN KINASES; SIRTUINS; STILBENES;

BODY COMPOSITION; CLINICAL STUDY; DRUG EFFECT; ENERGY EXPENDITURE; HUMAN; INSULIN SENSITIVITY; LIPID STORAGE; MUSCLE MITOCHONDRION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADIPOSE TISSUE, BROWN; ANIMALS; DRUG EFFECTS; HUMANS; METABOLISM; MITOCHONDRIA;

ANIMALIA; RODENTIA;

ADIPOSE TISSUE, BROWN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; MITOCHONDRIA; OBESITY; SIRTUINS; STILBENES;

EID: 84925424159     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.11.012     Document Type: Review

References (83)

1. Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:766-781.
2. Deivanayagam S., Mohammed B.S., Vitola B.E., Naguib G.H., Keshen T.H., Kirk E.P., Klein S. Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. Am. J. Clin. Nutr. 2008, 88:257-262.
3. Korenblat K.M., Fabbrini E., Mohammed B.S., Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.
4. Fabbrini E., Mohammed B.S., Magkos F., Korenblat K.M., Patterson B.W., Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008, 134:424-431.
5. Bournat J.C., Brown C.W. Mitochondrial dysfunction in obesity. Curr. Endocrinol. Diabetes. Obes. 2010, 17:446-452.
6. Larson-Meyer D.E., Newcomer B.R., Heilbronn L.K., Volaufova J., Smith S.R., Alfonso A.J., Lefevre M., Rood J.C., Williamson D.A., Ravussin E., et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 2008, 16:1355-1362.
7. Civitarese A.E., Carling S., Heilbronn L.K., Hulver M.H., Ukropcova B., Deutsch W.A., Smith S.R., Ravussin E., Team C.P. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007, 4:e76.
8. Nonomura S., Kanagawa H., Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-J O-Kon. (Polygonum cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi 1963, 83:988-990.
9. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
10. Sauve A.A., Wolberger C., Schramm V.L., Boeke J.D. The biochemistry of sirtuins. Annu. Rev. Biochem. 2006, 75:435-465.
11. Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan F., Ido Y. AMPK and SIRT1: a long-standing partnership?. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E751-E760.
12. Yu J., Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann. N. Y. Acad. Sci. 2009, 1173(Suppl. 1):E10-E19.
13. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S., et al. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14:612-622.
14. Dube J.J., Amati F., Stefanovic-Racic M., Toledo F.G., Sauers S.E., Goodpaster B.H. Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E882-E888.
15. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi Fanelli F., Patterson B.W., et al. Resveratrol supplementation does not improve metabolic function in nonobese postmenopausal women with normal glucose tolerance. Cell Metab. 2012, 16:658-664.
16. Canto C., Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol. Rev. 2012, 64:166-187.
17. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., Agarwal B., Ye L., Ramadori G., Teodoro J.S., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
18. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
19. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
20. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., Kim M.K., Viollet B., Chung J.H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
21. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
22. Bachmann O.P., Dahl D.B., Brechtel K., Machann J., Haap M., Maier T., Loviscach M., Stumvoll M., Claussen C.D., Schick F., et al. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001, 50:2579-2584.
23. Schrauwen-Hinderling V.B., Kooi M.E., Hesselink M.K., Moonen-Kornips E., Schaart G., Mustard K.J., Hardie D.G., Saris W.H., Nicolay K., Schrauwen P. Intramyocellular lipid content and molecular adaptations in response to a 1-week high-fat diet. Obes. Res. 2005, 13:2088-2094.
24. 1H NMR spectroscopy study. Diabetologia 1999, 42:113-116.
25. Blaak E.E., van Aggel-Leijssen D.P., Wagenmakers A.J., Saris W.H., van Baak M.A. Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes 2000, 49:2102-2107.
26. Mensink M., Blaak E.E., van Baak M.A., Wagenmakers A.J., Saris W.H. Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 2001, 50:2548-2554.
27. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
28. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
29. Patti M.E., Butte A.J., Crunkhorn S., Cusi K., Berria R., Kashyap S., Miyazaki Y., Kohane I., Costello M., Saccone R., et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8466-8471.
30. Meex R.C., Schrauwen-Hinderling V.B., Moonen-Kornips E., Schaart G., Mensink M., Phielix E., van de Weijer T., Sels J.P., Schrauwen P., Hesselink M.K. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 2010, 59:572-579.
31. Menshikova E.V., Ritov V.B., Toledo F.G., Ferrell R.E., Goodpaster B.H., Kelley D.E. Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E818-E825.
32. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
33. Chen L.L., Zhang H.H., Zheng J., Hu X., Kong W., Hu D., Wang S.X., Zhang P. Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation. Metabolism 2011, 60:1598-1609.
34. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
35. Kim S., Jin Y., Choi Y., Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem. Pharmacol. 2011, 81:1343-1351.
36. Dal-Pan A., Blanc S., Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010, 10:11.
37. Dal-Pan A., Terrien J., Pifferi F., Botalla R., Hardy I., Marchal J., Zahariev A., Chery I., Zizzari P., Perret M., et al. Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in Microcebus murinus. Age (Dordr) 2011, 33:15-31.
38. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84:277-359.
39. Andrade J.M., Frade A.C., Guimaraes J.B., Freitas K.M., Lopes M.T., Guimaraes A.L., de Paula A.M., Coimbra C.C., Santos S.H. Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur. J. Nutr. 2014, 53:1503-1510.
40. Alberdi G., Rodriguez V.M., Miranda J., Macarulla M.T., Churruca I., Portillo M.P. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem. 2013, 141:1530-1535.
41. Tseng Y.H., Kokkotou E., Schulz T.J., Huang T.L., Winnay J.N., Taniguchi C.M., Tran T.T., Suzuki R., Espinoza D.O., Yamamoto Y., et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008, 454:1000-1004.
42. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T., Taittonen M., Laine J., Savisto N.J., Enerback S., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360:1518-1525.
43. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32:537-541.
44. Crandall J.P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., Cohen H.W., Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:1307-1312.
45. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S.B., Jorgensen J.O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
46. Movahed A., Nabipour I., Lieben Louis X., Thandapilly S.J., Yu L., Kalantarhormozi M., Rekabpour S.J., Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Alternat. Med. 2013, 2013:851267.
47. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
48. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29:698-706.
49. Kang W., Hong H.J., Guan J., Kim D.G., Yang E.J., Koh G., Park D., Han C.H., Lee Y.J., Lee D.H. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012, 61:424-433.
50. Jeon B.T., Jeong E.A., Shin H.J., Lee Y., Lee D.H., Kim H.J., Kang S.S., Cho G.J., Choi W.S., Roh G.S. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012, 61:1444-1454.
51. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., Wang Y., Raederstorff D., Morrow J.D., Leeuwenburgh C., et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3:e2264.
52. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6:307-319.
53. Marchal J., Blanc S., Epelbaum J., Aujard F., Pifferi F. Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One 2012, 7:e34289.
54. Jimenez-Gomez Y., Mattison J.A., Pearson K.J., Martin-Montalvo A., Palacios H.H., Sossong A.M., Ward T.M., Younts C.M., Lewis K., Allard J.S., et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab. 2013, 18:533-545.
55. Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sulliva T.M., Lee P., Franklin M., Klein K., Taylor P.J., Ferguson M., et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014, 12:2092-2103.
56. Dash S., Xiao C., Morgantini C., Szeto L., Lewis G.F. High-dose resveratrol treatment for 2weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2895-2901.
57. Magyar K., Halmosi R., Palfi A., Feher G., Czopf L., Fulop A., Battyany I., Sumegi B., Toth K., Szabados E. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50:179-187.
58. Elliott P.J., Walpole S., Morelli L., Lambert P.D., Lunsmann W., Westphal C.H., Lavu S. Resveratrol/SRT-501. Drugs Future 2009, 34.
59. Brasnyo P., Molnar G.A., Mohas M., Marko L., Laczy B., Cseh J., Mikolas E., Szijarto I.A., Merei A., Halmai R., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106:383-389.
60. van Herpen N.A., Schrauwen-Hinderling V.B., Schaart G., Mensink R.P., Schrauwen P. Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men. J. Clin. Endocrinol. Metab. 2011, 96:E691-E695.
61. WGO Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, global guideline. WGO Global Guidelines 2012, 1-29.
62. Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009, 9:327-338.
63. Rodgers J.T., Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12861-12866.
64. Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., Wu S.Y., Chiang C.M., Veenstra T.D., Kemper J.K. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 2010, 285:33959-33970.
65. Walker A.K., Yang F., Jiang K., Ji J.Y., Watts J.L., Purushotham A., Boss O., Hirsch M.L., Ribich S., Smith J.J., et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010, 24:1403-1417.
66. Alberdi G., Rodriguez V.M., Macarulla M.T., Miranda J., Churruca I., Portillo M.P. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013, 29:562-567.
67. Poulsen M.M., Larsen J.O., Hamilton-Dutoit S., Clasen B.F., Jessen N., Paulsen S.K., Kjaer T.N., Richelsen B., Pedersen S.B. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr. Res. 2012, 32:701-708.
68. Heeboll S., Thomsen K.L., Pedersen S.B., Vilstrup H., George J., Gronbaek H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J. Hepatol. 2014, 6:188-198.
69. Xin P., Han H., Gao D., Cui W., Yang X., Ying C., Sun X., Hao L. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem. Toxicol. 2013, 52:12-18.
70. Cho I.J., Ahn J.Y., Kim S., Choi M.S., Ha T.Y. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367:190-194.
71. Zhou M., Wang S., Zhao A., Wang K., Fan Z., Yang H., Liao W., Bao S., Zhao L., Zhang Y., et al. Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. J. Proteome Res. 2012, 11:4961-4971.
72. Cho S.J., Jung U.J., Choi M.S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br. J. Nutr. 2012, 108:2166-2175.
73. Chen Q., Wang E., Ma L., Zhai P. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis. 2012, 11:56.
74. Bai Y., Mao Q.Q., Qin J., Zheng X.Y., Wang Y.B., Yang K., Shen H.F., Xie L.P. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010, 101:488-493.
75. Do G.M., Jung U.J., Park H.J., Kwon E.Y., Jeon S.M., McGregor R.A., Choi M.S. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol. Nutr. Food Res. 2012, 56:1282-1291.
76. Ahn J., Cho I., Kim S., Kwon D., Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J. Hepatol. 2008, 49:1019-1028.
77. Gomez-Zorita S., Fernandez-Quintela A., Macarulla M.T., Aguirre L., Hijona E., Bujanda L., Milagro F., Martinez J.A., Portillo M.P. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr. 2012, 107:202-210.
78. Franco J.G., Lisboa P.C., Lima N.S., Amaral T.A., Peixoto-Silva N., Resende A.C., Oliveira E., Passos M.C., Moura E.G. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J. Nutr. Biochem. 2013, 24:960-966.
79. Gao M., Liu D. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice. AAPS J. 2013, 15:744-752.
80. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., Garcia-Urkia N., Sarasqueta C., Cosme A., Irastorza B., Gonzalez A., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008, 8:40.
81. Li L., Hai J., Li Z., Zhang Y., Peng H., Li K., Weng X. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem. Toxicol. 2014, 63:166-173.
82. Tauriainen E., Luostarinen M., Martonen E., Finckenberg P., Kovalainen M., Huotari A., Herzig K.H., Lecklin A., Mervaala E. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J. Nutr. Metab. 2011, 2011:525094.
83. Farmer S.R. Obesity: be cool, lose weight. Nature 2009, 458:839-840.